GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Debt-to-Asset

Anavex Life Sciences (STU:12X1) Debt-to-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences Debt-to-Asset?

Anavex Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Anavex Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Anavex Life Sciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was €118.46 Mil. Anavex Life Sciences's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Anavex Life Sciences Debt-to-Asset Historical Data

The historical data trend for Anavex Life Sciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Debt-to-Asset Chart

Anavex Life Sciences Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anavex Life Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anavex Life Sciences's Debt-to-Asset

For the Biotechnology subindustry, Anavex Life Sciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anavex Life Sciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Debt-to-Asset falls into.


;
;

Anavex Life Sciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Anavex Life Sciences's Debt-to-Asset for the fiscal year that ended in Sep. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 122.146
=0.00

Anavex Life Sciences's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 118.461
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences  (STU:12X1) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Anavex Life Sciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Debt-to-Asset
Comparable Companies
COGT BCAX FTRE PRTA LENZ PRAX XNCR ABCL CMRX GHRS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
AVXL:USA 0HFR:UK 12X1:Germany
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Website
https://www.anavex.com
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Anavex Life Sciences Headlines

No Headlines